Cargando…
The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology
Tumour-associated macrophages (TAMs) are essential players in the tumour microenvironment (TME) and modulate various pro-tumorigenic functions such as immunosuppression, angiogenesis, cancer cell proliferation, invasion and metastasis, along with resistance to anti-cancer therapies. TAMs also mediat...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741298/ https://www.ncbi.nlm.nih.gov/pubmed/36497148 http://dx.doi.org/10.3390/cells11233890 |
_version_ | 1784848284404154368 |
---|---|
author | Vanmeerbeek, Isaure Govaerts, Jannes Laureano, Raquel S. Sprooten, Jenny Naulaerts, Stefan Borras, Daniel M. Laoui, Damya Mazzone, Massimiliano Van Ginderachter, Jo A. Garg, Abhishek D. |
author_facet | Vanmeerbeek, Isaure Govaerts, Jannes Laureano, Raquel S. Sprooten, Jenny Naulaerts, Stefan Borras, Daniel M. Laoui, Damya Mazzone, Massimiliano Van Ginderachter, Jo A. Garg, Abhishek D. |
author_sort | Vanmeerbeek, Isaure |
collection | PubMed |
description | Tumour-associated macrophages (TAMs) are essential players in the tumour microenvironment (TME) and modulate various pro-tumorigenic functions such as immunosuppression, angiogenesis, cancer cell proliferation, invasion and metastasis, along with resistance to anti-cancer therapies. TAMs also mediate important anti-tumour functions and can clear dying cancer cells via efferocytosis. Thus, not surprisingly, TAMs exhibit heterogeneous activities and functional plasticity depending on the type and context of cancer cell death that they are faced with. This ultimately governs both the pro-tumorigenic and anti-tumorigenic activity of TAMs, making the interface between TAMs and dying cancer cells very important for modulating cancer growth and the efficacy of chemo-radiotherapy or immunotherapy. In this review, we discuss the interface of TAMs with cancer cell death from the perspectives of cell death pathways, TME-driven variations, TAM heterogeneity and cell-death-inducing anti-cancer therapies. We believe that a better understanding of how dying cancer cells influence TAMs can lead to improved combinatorial anti-cancer therapies, especially in combination with TAM-targeting immunotherapies. |
format | Online Article Text |
id | pubmed-9741298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97412982022-12-11 The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology Vanmeerbeek, Isaure Govaerts, Jannes Laureano, Raquel S. Sprooten, Jenny Naulaerts, Stefan Borras, Daniel M. Laoui, Damya Mazzone, Massimiliano Van Ginderachter, Jo A. Garg, Abhishek D. Cells Review Tumour-associated macrophages (TAMs) are essential players in the tumour microenvironment (TME) and modulate various pro-tumorigenic functions such as immunosuppression, angiogenesis, cancer cell proliferation, invasion and metastasis, along with resistance to anti-cancer therapies. TAMs also mediate important anti-tumour functions and can clear dying cancer cells via efferocytosis. Thus, not surprisingly, TAMs exhibit heterogeneous activities and functional plasticity depending on the type and context of cancer cell death that they are faced with. This ultimately governs both the pro-tumorigenic and anti-tumorigenic activity of TAMs, making the interface between TAMs and dying cancer cells very important for modulating cancer growth and the efficacy of chemo-radiotherapy or immunotherapy. In this review, we discuss the interface of TAMs with cancer cell death from the perspectives of cell death pathways, TME-driven variations, TAM heterogeneity and cell-death-inducing anti-cancer therapies. We believe that a better understanding of how dying cancer cells influence TAMs can lead to improved combinatorial anti-cancer therapies, especially in combination with TAM-targeting immunotherapies. MDPI 2022-12-02 /pmc/articles/PMC9741298/ /pubmed/36497148 http://dx.doi.org/10.3390/cells11233890 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Vanmeerbeek, Isaure Govaerts, Jannes Laureano, Raquel S. Sprooten, Jenny Naulaerts, Stefan Borras, Daniel M. Laoui, Damya Mazzone, Massimiliano Van Ginderachter, Jo A. Garg, Abhishek D. The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology |
title | The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology |
title_full | The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology |
title_fullStr | The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology |
title_full_unstemmed | The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology |
title_short | The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology |
title_sort | interface of tumour-associated macrophages with dying cancer cells in immuno-oncology |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741298/ https://www.ncbi.nlm.nih.gov/pubmed/36497148 http://dx.doi.org/10.3390/cells11233890 |
work_keys_str_mv | AT vanmeerbeekisaure theinterfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT govaertsjannes theinterfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT laureanoraquels theinterfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT sprootenjenny theinterfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT naulaertsstefan theinterfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT borrasdanielm theinterfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT laouidamya theinterfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT mazzonemassimiliano theinterfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT vanginderachterjoa theinterfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT gargabhishekd theinterfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT vanmeerbeekisaure interfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT govaertsjannes interfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT laureanoraquels interfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT sprootenjenny interfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT naulaertsstefan interfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT borrasdanielm interfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT laouidamya interfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT mazzonemassimiliano interfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT vanginderachterjoa interfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology AT gargabhishekd interfaceoftumourassociatedmacrophageswithdyingcancercellsinimmunooncology |